Beijing Draws a Line: What China's Proposed Biopharma Export Ban Means for the Global Deal Machine

For the past two years, the story of global pharmaceutical dealmaking has been, in large part, a story about China. Western companies have signed licensing agreements with Chinese biotechs at a pace that would have seemed implausible a decade ago, paying billions of dollars in upfront and milestone payments for drugs developed in Shanghai, Suzhou, and Shenzhen. The numbers are striking: foreign transactions involving Chinese biotech assets reached $120 billion as of August 2026, a 36 percent jump year over year. The pipeline flowing out of China has reshaped how major pharmaceutical companies think about early-stage drug discovery, and it has made China one of the most consequential sources of innovation in the global industry.

On October 16, 2026, Beijing moved to put guardrails around that pipeline. China's Ministry of Commerce and Ministry of Science and Technology published a draft policy that would ban foreign acquisitions of proprietary cell and gene therapy, small interfering RNA, and pathogen gain-of-function platforms. A parallel restriction would require regulatory approval for the full transfer of drug target identification and verification technologies in those same fields. The comment period runs until November 15. The policy is not yet final. But its publication marks a meaningful shift in how China is thinking about the relationship between its biotech sector and the rest of the world.

What the Rule Actually Does, and Does Not Do

The most important thing to understand about this draft policy is what it explicitly excludes. Out-licensing agreements, the dominant structure in virtually every major China-to-West biopharma deal of the past several years, are not covered by the ban. A Chinese biotech can still license a drug candidate to Roche, AstraZeneca, or Pfizer, collect an upfront payment, and receive royalties and milestones as the drug advances through development. That structure, which accounts for the overwhelming majority of cross-border Chinese biopharma transactions, remains fully intact.

What the rule targets is ownership transfer of the underlying platform itself. According to data from PharmCube, a Chinese biopharma intelligence service, only five of 121 cross-border Chinese biopharma out-licensing deals completed in 2026 through July involved an ownership transfer. The deal that would most clearly have been blocked under the proposed rule is AstraZeneca's $1 billion acquisition of Gracell Biotechnologies in 2023, which handed AZ full ownership of Gracell's FasTCAR cell therapy manufacturing platform. That kind of transaction, where a foreign buyer acquires not just a drug but the engine that produces drugs, is precisely what Beijing is seeking to prevent.

Aaron Gu, a partner at Han Kun law firm specializing in healthcare and life sciences, described the published draft as "significantly better than market expectations." Earlier rumors had suggested the government might restrict a far broader range of modalities, including multispecific antibodies, antibody-drug conjugates, and protein degraders. The final draft is considerably more targeted, and Gu noted that by "deliberately excluding out-licensing structures, the government has clearly taken into account biopharma dealmaking norms and the momentum of cross-border collaboration."

The Logic Behind the Policy

The Chinese government's rationale, as articulated in a Ministry of Commerce media briefing, is about preserving domestic capability rather than restricting international collaboration. The concern is a phenomenon that Chinese industry insiders have called "selling green shoots," where early-stage Chinese biotechs, lacking the capital and experience to run late-stage global trials, sell their most promising platform technologies outright to foreign acquirers. The result, from Beijing's perspective, is that China provides the scientific foundation while foreign companies capture the long-term commercial and technological value.

That concern is not unreasonable. The cell and gene therapy and siRNA fields represent some of the most consequential platform technologies in modern medicine. A country that builds deep expertise in these areas and then allows that expertise to be acquired wholesale by foreign entities is, in a meaningful sense, exporting its innovation capacity rather than its products. The proposed rule attempts to draw a line between the two: China will continue to export drugs, but it will retain ownership of the machines that make them.

A Mirror Image of Washington's Concerns

The timing of Beijing's move is not incidental. It arrives as Washington is simultaneously tightening its own scrutiny of Chinese biopharma transactions. Congressional Representative John Moolenaar and Congresswoman Debbie Dingell have introduced the Biotech Investment National Security Act, which would subject China biopharma deals to additional review. The U.S. Treasury Department is working on rules that would likely preserve most licensing deals while adding oversight mechanisms. Both governments, from opposite directions, are arriving at a similar conclusion: the free flow of biopharma platform technology across the US-China divide carries strategic risks that pure commercial logic does not adequately account for.

The result is a regulatory environment that is becoming more complex for companies operating in both markets. For Western pharmaceutical companies that have built China-sourcing strategies around licensing deals, the immediate practical impact of the proposed rule is limited. The deal structures they use are explicitly preserved. But the direction of travel is clear, and companies that have been considering platform acquisitions in China, rather than licensing arrangements, will need to move quickly or reconsider their approach before the comment period closes and the rule takes effect.

What This Means for the Industry

The broader implication of China's proposed export controls is that the era of unconstrained cross-border biopharma platform acquisition is ending. The licensing model, which has driven the most active period of China-to-West dealmaking in history, is not threatened. But the model that would allow a foreign company to buy a Chinese siRNA or cell therapy platform outright, gaining full ownership of the underlying technology and the team that built it, is being foreclosed. That distinction matters for how the next generation of deals will be structured, and for how Western companies think about the depth of their strategic relationships with Chinese partners.

For the Chinese biotech sector, the rule is a signal that Beijing views its most advanced platform technologies as national assets, not just commercial products. Whether that framing ultimately serves Chinese biotechs well, by preserving their long-term leverage, or constrains them, by limiting the exit options available to founders and investors, will depend on how the rule is implemented and how the broader geopolitical environment evolves. The comment period closes November 15. The industry will be watching closely.